STO-609 acetate

STO-609 acetate purchased from MedChemExpress. Usage Cited in: Nat Aging. 2025 Jun;5(6):1097-1113. [Abstract]

Customer Validation
Primary WT mouse neurons were treated with exendin-4 with or without STO-609, a CaMKK2 inhibitor. STO-609 significantly attenuated the effect of exendin-4 on AMPK phosphorylation.

STO-609 acetate purchased from MedChemExpress. Usage Cited in: Nat Metab. 2022 Sep;4(9):1185-1201. [Abstract]

Customer Validation
Mouse primary hepatocytes were incubated with ¹³C acetate (1 mM) containing vehicle control (PBS), ORM2 (100 ng ml−1) and STO-609 (5 μM) for 6 h. STO-609 markedly abolished suppression of DNL rate by ORM2 in primary hepatocytes from C57BL/6J healthy mice.

STO-609 acetate purchased from MedChemExpress. Usage Cited in: Nat Metab. 2022 Sep;4(9):1185-1201. [Abstract]

Customer Validation
MPHs were pre-incubated with palmitic acid (200 μM) for 12 hr, and then treated with ORM2 protein (100 ng/ml) or vehicle control (PBS) for 6 h, in the presence or absence of STO-609 (5 μM). STO-609 largely blocked the inhibitory effects of ORM2 on cellular TG accumulation and lipogenic gene expression.

STO-609 acetate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2021 Jan 25;6(1):29. [Abstract]

Customer Validation
Cells were pretreated with STO-609 (10 μM; 1 h) followed by exposure to NM (20 μM) for an additional 24 h. STO-609 markedly inhibited NM-induced AMPK and ULK1 activation.

STO-609 acetate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2021 Jan 25;6(1):29. [Abstract]

Customer Validation
Cells were treated with STO-609 (10 µM; 1 h) following the addition of NM (20 µM) for another 24 h. Total cell lysates were collected and the levels of indicated proteins were detected by western blotting. STO-609 treatment markedly inhibited NM-induced ULK1 activation and autophagy induction but had no obvious effect on NM-induced pmTOR expression in keratinocytes.